Summary
The semi-synthetic vinca alkaloid vinzolidine was administered to advanced cancer patients as an intravenous bolus on a three day schedule every 21 days. Forty-two patients were treated in this phase I trial. Five partial remissions (breast-1, melanoma-2, renal cancer-2) were seen in 30 evaluable patients. The dose limiting toxicities were myelosuppression and neuropathy. Erratic myelosuppression from course to course within the same patient as seen in previous trials with oral vinzolidine, was not observed with the intravenous formulation. The measured pharmacokinetic parameters conformed best to a 2-compartment model with a mean terminal half-life of 23 hours. The anti-tumor activity observed during this phase I trial and acceptable toxicity provide the basis for initiating phase II studies in selected forms of cancer.
Similar content being viewed by others
References
Takasugi BJ, Robertone AB, Salmon SE, Alberts DS: Fiveday schedule of vinzolidine, an oral vinca alkaloid, in a variety of tumors. Invest New Drugs 2: 387–390, 1984
Takasugi BJ, Salmon SE, Nelson RL, Young L, Liu RM: Antitumor activity of vinzolidine in the human tumor clonogenic assay and comparison with vinblastine. Invest New Drugs 2: 49–53, 1984
Takasugi BJ, Jones SE, Robertone AB: Phase II trial of vinzolidine, an oral vinca alkaloid in Hodgkin's disease and non-Hodgkin's lymphoma. Cancer Treat Rep 68: 1399–1401, 1984
Budman DR, Schulman P, Marks M, Vinciguerra V, Weiselberg L, Kreis W, Degnan TJ: Phase I trial of vinzolidine. Cancer Treat Rep 68: 979–982, 1984
Sarna G, Mitsuyasu R, Figlin R, Ambersley J, Groopman J: Oral vinzolidine as therapy for Kaposi's sarcoma and carcinomas of lung, breast, and colon/rectum. Cancer Chemother and Pharmacol 14: 12–14, 1985
Nelson R: Clinical pharmacology of vinzolidine, a new orally active vinca alkaloid derivative (Abstr). Proc Amer SocClin Oncol 1: 19, 1983
Sethi VS, Burton SS, Jackson DV: A sensitive radioimmunoassay for vincristine and vinblastine. Cancer Chemother Pharmacol 4: 183–187, 1980
Weiner DL: NONLIN 84/PCNONLIN: Software for the statistical analysis of nonlinear models. Meth and Find Exp Clin Pharmacol 8: 625–628, 1986
Boxenbaun HG, Riegelman S, Elashoff RM: Statistical estimations in pharmacokinetics. J Pharmacokin Biopharm 2: 123–143, 1974
Bender RA, Chabner BH: Tubulin binding agents. In: Chabner BA (ed) Pharmacologic Principles of Cancer Treatment, W.B. Saunders, Philadelphia, 1982, pp 256–268
Nelson RL, Dyke RW, Root MA: Comparative pharmacokinetics of vindesine, vincristine and vinblastine in patients with cancer. Cancer Treat Rev 7 [Suppl]: 17–24, 1980
Owellen RJ, Hartke CA, Hains FO: Pharmacokinetics and metabolism of vinblastine in humans. Cancer Res 37: 2597–2602, 1977
Author information
Authors and Affiliations
Additional information
Dr. Taylor is the recipient of a Clinical Oncology Career Development Award from the American Cancer Society.
Rights and permissions
About this article
Cite this article
Taylor, C.W., Salmon, S.E., Satterlee, W.G. et al. A phase I and pharmacokinetic study of intravenous vinzolidine. Invest New Drugs 8 (Suppl 1), S51–S57 (1990). https://doi.org/10.1007/BF00171984
Issue Date:
DOI: https://doi.org/10.1007/BF00171984